Alnylam Pharmaceuticals, Inc. (ALNY) shares fell 6.54 percent, declining $21.05 to $300.70 on Thursday even after the company reported a fourth-quarter profit compared with a loss a year earlier.
The stock opened at $314.42, down from a previous close of $321.75, and has traded between $298.00 and $315.51 during the session on the Nasdaq. The last reported bid was $300.00 for 100 shares, with the ask at $309.98 for 100 shares. Trading volume reached 552,594 shares, below the average volume of 1,494,936.
Alnylam shares have traded within a 52-week range of $205.87 to $495.55.
Net income for the quarter was $111.5 million, or $0.82 per share, compared with a loss of $83.8 million, or $0.65 per share, last year. On an adjusted basis, earnings per share increased to $1.25 from $0.06. Total revenues nearly doubled to $1.10 billion from $593.17 million, while net product revenues rose to $994.7 million from $450.8 million.
For 2026, the company projects total net product revenues in a range of $4.9 billion to $5.3 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.